1

1	Original article
2	
3	
4	INSIGHT: A Tool for Fit-for-Purpose Evaluation and Quality
	Assessment of Observational Data Sources for Real World
5	
6	Evidence on Medicine and Vaccine Safety
7	
8	
9	
10	
11	Vjola Hoxhaj ¹ (<u>v.hoxhaj@umcutrecht.nl</u>)
12	Constanza L. Andaur Navarro ¹ (c.l.andaurnavarro@umcutrecht.nl)
13 14	Judit Riera-Arnau ^{1,2} (<u>j.rieraarnau@umcutrecht.nl</u>) Roel JHJ Elbers ¹ (<u>roelelbers@hotmail.com</u>)
14 15	Ema Alsina ¹ (<u>palsinaaer@gmail.com</u>)
16	Caitlin Dodd ¹ (<u>caitlinndodd@gmail.com</u>)
17	Miriam CJM Sturkenboom ¹ (<u>m.c.j.sturkenboom@umcutrecht.nl</u>)
18	
19 20 21 22 23 24 25 26 27 28	
29	¹ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University,
30	Utrecht, The Netherlands.
31	² Clinical Pharmacology Service, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus,
32	Universitat Autònoma de Barcelona, Barcelona, Spain.
33	
34	
35	Word count: 3705/4000
36	
37	Keywords: data quality assessment, quality checks, level checks, real-world data, common data
38	model, pregnancy, drug safety, multi-database studies.
39	
40	Corresponding author: Constanza L. Andaur Navarro, c.l.andaurnavarro@umcutrecht.nl
41	Julius Centre for Health Sciences and Primary Care, Universiteitsweg 100, P.O. Box 85500, 3508 GA,
42	Utrecht, The Netherlands

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

43 ABSTRACT

- 44 **Objective.** To describe the development of INSIGHT, a real-world data quality tool to assess 45 completeness, consistency, and fitness-for-purpose of observational health data sources.
- Material and Methods. We designed a three-level pipeline with data quality assessments 46 47 (DQAs) to be performed in ConcePTION Common Data Model (CDM) instances. The pipeline 48 has been coded using R.
- 49 **Results.** INSIGHT is an open-source tool that identifies potential data quality issues in CDM-50 standardized instances through the systematic execution and summary of over 588 configurable DQAs. Level 1 focuses on compliance with the ConcePTION CDM specifications. 51 52 Level 2 evaluates the temporal plausibility of events and uniqueness of records. Level 3 53 provides an overview of distributions, outliers, and trends over time. The DQAs are run locally 54 and assessed centrally by a data quality revisor together with the data access provider's 55 representatives.
- 56 **Discussion.** INSIGHT aligns with recent conceptual frameworks that identify five dimensions 57 of data quality: reliability, extensiveness, coherence, timeliness, and relevance. Data quality 58 is the sum of several internal and external features of the data and while DQAs provide 59 reassurance about fitness-for-purpose for secondary-use data sources, improvements in data 60 collection and generation stages are essential to reduce bias, misclassification, and 61 measurement errors, thereby enhance overall data quality for Real World Evidence.
- **Conclusion.** INSIGHT aims to support clinical and regulatory decision-making for medicines 62 and vaccines by evaluating the quality of observational health data sources to support fit for 63 64 purpose assessment. Assessing and improving data quality will enhance the reliability and 65 quality of the generated evidence.
- 66
- 67 Word count: 246/250

68 INTRODUCTION

Regulatory agencies and healthcare professionals acknowledge and underline the 69 70 significance of Real-World Data (RWD) in informing clinical decisions and shaping public 71 health policies, especially for populations underrepresented in clinical trials, such as pregnant 72 women.^{1,2} Pharmacoepidemiologists have used RWD since the 90s, and worked in distributed 73 networks to expedite the generation of Real-World evidence (RWE) for regulatory decision 74 making. In such networks, multiple data access providers (DAPs) collaborate by handling 75 heterogeneous data and using the state-of-the-art approach to generate RWE. This involves 76 the use of a common protocol, a common data model and common analytics with tools, which 77 have been improving over the past 15 years.³ Comprehensive analyses of these approaches 78 have been published.⁴

79 The lack of knowledge regarding the use and safety of medicines and vaccines during 80 pregnancy and lactation is widely recognized. Studies indicate that 70-90% of women are 81 exposed to a prescription medicine during pregnancy.⁵ However, the process of determining 82 the teratogenic status of a novel medication currently takes 27 years.⁶ To close this evidence gap, the IMI ConcePTION project was established (www.imi-conception.eu), bringing together 83 84 88 stakeholders across Europe with the aim to create a learning healthcare ecosystem to 85 support future studies on safety of medicines and vaccines during pregnancy and lactation. ConcePTION uses RWD to generate Real World Evidence (RWE) for childbearing-aged, 86 87 pregnant, and lactating women, and their offspring.

Before conducting any analysis using RWD, it is imperative to ensure the quality of the data 88 89 and Data Quality Assessments (DQAs) should be conducted to evaluate whether data sources 90 are fit for purpose prior to study initiation. ConcePTION along with other research networks 91 such as US Food and Drug Administration (FDA) Sentinel, PCORnet, and the Observational 92 Health Data Science and Informatics program (OHDSI) perform DQAs on the data loaded into common data models (CDM) used by these networks for distributed analyses.^{7–9} The 93 94 ConcePTION CDM allows for syntactic harmonization of heterogeneous data sources, and enables fitness-for-use and fitness-for-purpose evaluations.¹⁰ As part of the ConcePTION 95 96 project, we have developed INSIGHT, a generic RWD tool to perform DQAs on ConcePTION 97 CDM-standardized data sources ensuring data guality and the generation of reliable evidence 98 for pharmacoepidemiologic studies. This tool aligns with Kahn's data quality framework which 99 encompasses three main quality dimensions: conformance, completeness, and plausibility.¹¹

100 In this article, we describe INSIGHT, an open-source tool that comprises three levels of DQAs 101 and we outline step-by-step its design and execution. Furthermore, we present an overview 102 of the DQA workflow, including processes, visualizations, and responsible parties. We show

103 examples of detected inconsistencies and errors, which serve as proof-of-concept, highlighting the tool's effectiveness in identifying and addressing data quality issues. 104

- **METHODS** 105
- As part of a common analytics and distributed analytics framework, Data Access Providers 106
- 107 (DAPs) are required to convert their local data sources into the ConcePTION CDM using an
- 108 Extract-Transform-Load (ETL) process. The ConcePTION CDM encompasses demographics,
- observation periods, medicines and vaccines exposure, events, procedures, mother-child 109
- 110 linkage, visits, and clinical observations. The current version 2.2 includes 16 tables (Box 1).
- Additional details can be found elsewhere.¹⁰ 111

Box 1. ConcePTION	I CDM tables	112
Routine	VISIT_OCCURRENCE	113
healthcare data	EVENTS	114
	MEDICINES	115
	PROCEDURES	116
	VACCINES	117
		118
-	MEDICAL_OBSERVATIONS	119
Surveillance	EUROCAT	120
	SURVEY_ID	121
	SURVEY_OBSERVATIONS	122
	EUROCAT	123
Curated tables	PERSONS	124
	OBSERVATION_PERIODS	125
	PERSON_RELATIONSHIPS	126
	PRODUCTS	127
	CDM_SOURCE	128
Metadata	METADATA	129
	CDM_SOURCE	130
	INSTANCE	131
	PRODUCTS	132

ConcePTION Common data model 133

When working on studies with the ConcePTION CDM, DAPs are asked to load their data into 134

135 a standardized data structure using the source values. This ensures that the ConcePTION

136 CDM is syntactically (ensuring consistency in the structure) harmonized. The ConcePTION

137 CDM pipeline does not require semantic harmonization (translation/mapping of source value

138 to common vocabularies), which can often be time consuming. Instead, mapping is conducted 139 as part of the study script, making it a transparent and flexible process. Once the data sources 140 are syntactically standardized, DQAs are performed to allow assessment of data quality and 141 fitness for purpose.

Objectives of Data Quality Assessments 142

Various conceptual data quality frameworks have been published over the last years.¹² For 143 the development of INSIGHT, we focused on the harmonized terminology for data quality 144 145 dimensions put forth by Khan et al., and the quality indicators established by the US FDA 146 Sentinel initiative, OHDSI, and the EUROCAT indicators for population-based healthcare data sources.^{11,13} By incorporating these frameworks, we aimed to create a comprehensive and 147 robust data quality verification pipeline for projects using the ConcePTION CDM. In Figure 1, 148 149 we show the hierarchy of DQAs in INSIGHT followed by a brief description.




Figure 1. Hierarchy and dimensions of data guality assessment in INSIGHT

150 Level 1 data quality indicators provide insight on the completeness and compliance of the ETL

151 process with the ConcePTION CDM specifications, ensuring format, structural and relational

coherence. In addition, the plausibility of the data and the uniqueness of records is addressed, 152

maintaining data integrity as well as identifying duplication errors. 153

154 Level 1b data quality indicators provide a list of all extracted and loaded non-date variables 155 across the ConcePTION CDM tables. The primary objective is to provide DAPs, principal 156 investigators, programmers, and analysts a comprehensive overview of the values of each 157 non-date variable to allow for study-specific variable definitions. This level aims to enhance 158 the understanding of the data content, facilitating semantic harmonization in the study scripts.

159 Level 2 data quality indicators provide an overview of the logical relationship and integrity of 160 values within and between variables and tables. Its purpose is to verify the temporal plausibility 161 by examining records that occur outside the recorded person-time, identifying observations 162 related to a person ID that is not present in the PERSONS table, among other similar 163 inconsistencies.

164 Level 3 data quality indicators provide distributions of population, diagnoses, medicines, 165 vaccines, lifestyle factors, pregnancy, and temporal trends over calendar time for each specific 166 variable. The primary objective is to allow for inspection of temporal changes in population, 167 follow-up, medicines, vaccines, and disease rates. These indicators can be compared 168 between instances and between DAPs, but also against external benchmarks to verify their 169 fitness for purpose.

170 To ensure that data quality indicators can be inspected, it is important to present the results 171 in a format that facilitates their understanding and sharing. To achieve this, HTML reports with 172 the presentation of the data quality indicators were developed. These reports contain summary 173 tables which allow for a concise representation of data quality indicators and graphs that 174 provide a visual representation of trends and patterns. INSIGHT has been implemented using 175 R scripts, which automate the running process of DQAs. The INSIGHT DQA is an iterative 176 process, each level can be rerun until the required quality is attained or all constraints are 177 noted.

178 **Design of Data Quality Indicators**

179 Level 1: Coherence and Completeness

180 Level 1 comprises five major steps (Box 2). Step 1 verifies the presence and format of variables ensuring their inclusion and adherence to the designated format. Step 2 verifies 181 missingness of values within the ConcePTION CDM and provides the extent of missing data 182 183 overall and by calendar year. Step 3 verifies whether date variables comply with the required format and validates day, month, and year values. Steps 1 to 3 are performed simultaneously 184 185 on all ConcePTION CDM tables, except for the METADATA table. The results are 186 consolidated into a single HTML report.

		HTML report
Step 0: METADATA	Checks the working directory and the consistent presence of all CDM tables and variables, irrespective of uppercase/lowercase and content	Yes
	Checks if all variables are written in lowercase.	-
Step 1: Checks the table formatting	Checks if all rows of the .csv files in the working directory contain the correct number of fields	Yes
	Checks if all variables are present irrespective of their content	-
	Checks if variables are written in lowercase	-
	Checks for presence of mandatory variables as according to the CDM	
	Checks for presence of non-mandatory variables by comparing between the table of interest and the information recorded in the METADATA table	
	Checks presence of vocabularies for specific variables	
	Assess the format for all values and compare to a list of acceptable formats which have been filled out in the METADATA table	
Step 2: Missing data analysis	Tabulate missingness in all variables, overall and by calendar year (in the tables that contain a date variable)	
	Missing data will be further stratified by data provenance* (in the tables that containing this variable) Missing data overall will be displayed using bar charts for each CDM	_
	table and reported as counts and percentages	
	Missing data stratified by data provenance or calendar year will be displayed using line charts for each CDM table and reported as counts and percentages	
	Missing data stratified by data provenance and calendar year will be displayed using faceted bar charts for each CDM table and reported as counts and percentages	
Step 3: Date variables	Checks if dates are in the correct format (8 characters) Checks if date variables contain allowable values:	
	Year: 1995(study specific)-present; Month: 01-12; Day: 01-31	
Intermediate step	High-level description of the CDM instance based on the information collected from CDM_SOURCES and INSTANCE tables	Yes
Step 4: Convention and counts of categorical variables	Checks if the table of interest contains any duplicate rows	Yes, per each CDM table
	Checks that all conventions for the table of interest have been adhered to	1
	Constructs frequency tables of categorical variables, overall and by calendar year (when the table of interest contains a date variable).	1
Step 5: Distribution of continuous variables and dates	For continuous variables mean, median, interquartile range, skewness and kurtosis will be reported.	Yes, per each CDM table
	Distribution of date variables will be reported as counts of dates overall and by calendar year.	

188 An intermediate step before Steps 4 to 5 generates a high-level characterization of the 189 ConcePTION CDM instance by extracting information from the CDM SOURCE and 190 INSTANCE tables, highlighting the key attributes of the data instance. A verification of uniqueness of records is also performed as duplicates check. Step 4 verifies compliance of 191 192 the ConcePTION CDM tables with the required conventions. These conventions are specific 193 to each CDM table and refer to the table structure and vocabulary rules. Moreover, frequency 194 tables are constructed for categorical variables, providing a summary of values. Step 5 195 produces the distribution of continuous variables and date variables. For continuous variables, 196 descriptive statistics such as mean, median, interquartile ranges are calculated. Steps 4 and 197 5 are performed separately for each CDM table. An HTML report is generated for each table, providing a separate overview of the results. All issues identified need to be fixed by updating 198 199 the ETL design, or when not possible will be noted. In summary, Level 1 DQA aims to verify 200 format coherence and completeness of each variable across the 15 CDM tables, 201 encompassing a total of 356 individual indicators. The code is available at 202 https://github.com/UMC-Utrecht-RWE/INSIGHT-Level1

203 Level 1b: Data characterization at value level

204 Level 1b relies on the successful conformance to the ConcePTION CDM specifications and 205 consists of two steps (Box 3). In this level, various aspects related to the data's coherence 206 and precision are evaluated through 26 checks (Box 3), including alignment of ATC codes at 207 the same pharmacological level, or consistency of treatment duration expression (days or 208 weeks) if available, among others. Level 1b does not generate an HTML report, but a set of 209 csv files for each CDM table. The code is available at https://github.com/UMC-Utrecht-

RWE/INSIGHT-Level1b 210

Box 3. D	etails on the quality checks involved in level 1b	
		HTML report
Step 1	Creates frequency tables for each variable within each CDM table by displaying counts of all values present.	No
Step 2	Creates contingency tables for categorical variables within each CDM table and shows the distribution of one variable across the categories of other variables.	No

9

211 Level 2: Data Relational logic characterization

- 212 Level 2 consists of 8 steps (Box 4) with a total of 57 indicators and verifies temporal plausibility
- 213 of date variables (Steps 2.1-2.3, 2.5-2.6) and consistency of encounter records across
- different tables (Steps 2.4, 2.7-2.8). For example, step 2.1 examines if health encounters 214
- 215 occurred before an individual's date of birth, ensuring the chronological integrity of the data.
- 216 Similarly, Step 2.4 verifies that person IDs with a record in any of the CDM tables are also
- 217 listed in the PERSONS table. The R-script is available at https://github.com/UMC-Utrecht-
- 218 RWE/INSIGHT-Level2

		HTML report
Step 1*	Checks dates of events before birth	Yes
Step 2*	Checks dates of events after death	Yes
Step 3*	Checks dates of events outside observation periods	Yes
Step 4*	Checks subjects observed in a CDM table of interest without a corresponding record in the PERSONS table	Yes
Step 5	Checks observations associated with a <i>visit_occurrence_id</i> which occur before the <i>visit_start_date</i> (optional, if the study cares of visits)	Yes
Step 6	Checks observations associated with a <i>visit_occurrence_id</i> which occur after the <i>visit_end_date</i> (optional, if the study uses variable visits)	Yes
Step 7	Checks observations associated with a <i>visit_occurrence_id</i> for which the associated <i>person_id</i> differs from that in the VISIT_OCCURRENCE table (optional)	Yes
Step 8	Checks for subjects indicated in PERSON_RELATIONSHIPS as the parent of a child whose birth date is less than 12 years prior to the recorded birth date of the linkage child (optional, if the study requires mother-child linkage)	Yes

219 Level 3: Data Content Characterization

220 Level 3 creates tables and graphics for study-variables (Box 5) in 9 steps. First the population, 221 its follow-up, and entry and exit patterns are described, allowing for verification of stability of 222 the dynamic population. Subsequently key study variables such as medicines, vaccines, 223 diagnoses, pregnancy, lifestyle factors and EUROCAT indicators are created in the study 224 population. All indicators result in graphics allowing to inspect temporal trends, including 225 person-time, prevalence of medicine prescriptions, and incidence of events for the study 226 population and subpopulations of interest. This allows for the identification of any peaks, 227 drops, or trends in the data and facilitates benchmarking between different instances, DAPs

10

228 and external data. There are three versions of the output provided, one with no masking 229 procedures applied, the two other versions allow for masking of cell counts. The first is 230 masking all counts lower than five, and the second does not show absolute counts but only

ranges. With over 249 indicators, Level 3 allows to deeply assess whether data is fit for 231

232 purpose. The code is available at https://github.com/UMC-Utrecht-RWE/INSIGHT-Level3

		HTML report
Step 0: Subpopulation availability*	Checks presence or absences of subpopulation* for iterative performance of level checks	No
Step 1: Study- source population	Checks counts, rates, and distributions of study population characteristics	Yes
Step 2: Dates	Checks the distribution of start-end, follow-up, and birth dates across time	Yes
Step 3: Visits and lifestyle	Checks counts and rates about lifestyle factors and use of healthcare facilities	Yes
Step 4: Medicines	Checks counts and rates across time of medicine use	Yes
Step 5: Vaccines	Checks counts and rates across time of vaccine exposure	Yes
Step 6: Diagnoses	Checks counts and rates across time of events of interest	Yes
Step 7: Pregnancy	Checks counts and rates of pregnant population stratified by status of pregnancy	Yes
Step 8: Population of interest	Checks counts and rates of events, medicine use and vaccine exposure distribution in a specific sub- group (e.g., pregnant women, subjects with a migraine diagnosis etc.)	Yes
Step 9: EUROCAT**	Data Quality Indicators on congenital anomalies information in Europe	Yes

provenance (i.e., hospital admission and general practitioner' data etc.) ** The number of quality checks and HTML reports will double per the number of subpopulations available on the data instance For DAPs with EUROCAT/EUROmediCAT data sources, steps 1 and

2 are mandatory.

233 **HTML** report

HTML reports are generated for Level 1, 2 and 3 outputs. Within Level 1 several reports are 234 235 created. The first report lists the presence of the METADATA table, a mandatory table, in the 236 working directory. The report on Step 1 to 3 provides information on the format coherence and 237 completeness. Reports Step 4 to 5 are optional and based on study specific requirements of 238 CDM tables (Box 1). Reports 1-4 in Level 2 are mandatory, whereas reports 5-8 are optional, 239 depending on study requirements (Box 3). Level 3 DQAs produce nine reports of which report 240 1 and 2 are mandatory. The total number of reports depends on the study requirements and 241 the number of subpopulations (Box 5). The output of level 1b is available as csv files and makes it possible to highlight any inconsistencies or create dictionaries for semantic 242 243 harmonization of non-harmonized values.

244 **Responsible Parties**

245 The R-scripts are available on the UMCU-RWE private GitHub and maintained by UMC 246 Utrecht. A public frozen version is available for this paper. DAPs are responsible for 247 downloading and running the R scripts locally and addressing issues related to table formatting 248 that results from Level 1 Step 1 to 3 and exceeding the *a-priori* 5% inconsistencies threshold 249 defined in Level 2. If any issues are reported, DAPs must revise the ETL of the data instance 250 and rerun these steps.

251 The outputs of the Level 1, 1b, 2 and 3 DQAs are uploaded to the UMCU Digital Research 252 Environment (DRE) by the DAPs, for centralized review by the data quality revisor and the DAPs.¹⁴ The data quality revisor collaborates with each DAP to address any issues flagged 253 254 during the revision, as DAPs can provide background information on data collection 255 processes, population characteristics, national healthcare system, availability of healthcare 256 facilities, regulatory aspects, and expected disease incidence and prevalence. Observations 257 are listed in the data quality approval form (Supplemental File 1). Data analytics engineers 258 provide technical support related to issues that get reported. Figure 2 shows the workflow.

12




Figure 2. Workflow of INSIGHT

259 Approval form

260 An approval form must be completed centrally by the DAP and the data quality revisor, with 261 one form per instance and per level check. This form serves as a quality assurance document 262 and systematically and transparently consolidates relevant information from the DQAs. The 263 form is an Excel document with four tabs, one per level check listing the relevant aspects to 264 be assessed per output (Supplemental File 1).

Training 265

266 As VAC4EU utilizes the ConcePTION CDM pipeline for its vaccine evaluation studies, they

267 have developed a training course dedicated to Data Quality checks. Investigators can register

268 and complete this course online. Upon successfully passing the final test, they will be awarded

269 certification. medRxiv preprint doi: https://doi.org/10.1101/2023.10.30.23297753; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

13

270 ILUSTRATIVE EXAMPLE

INSIGHT is available as a set of executable R scripts, currently supporting the use of
ConcePTION CDM version 2.2.^{15–18}

273 Level 1

- In Level 1, one of the key objectives is to assess conformance of the ETL'ed data to the
- 275 ConcePTION CDM specifications. For instance, if alternative values such as "1" for males and
- 276 "2" for females are used instead of the designated values (M, F, U, O) for the variable
- 277 sex_at_instance_creation in the PERSONS table, it will be flagged as an error in Steps 1 to 3
- 278 report.
- Additionally, Level 1 identifies unallowable values in date variables. In <u>Figure 3</u>, we show an example from the EVENTS table, the indicator *error_year* is displayed in blue, highlighting records with dates before 1995 or in the future. Most DAPs have data banks starting after 1995, that is why this cut off was chosen. The indicator *future_dates* show records with dates in the future in comparison to the script running date.
- DAPs are expected to resolve these issues by updating their ETL specifications to adhere tothe specified rules and requirements, if possible.

286 Level 1b

Level 1b allows users to visualize various aspects of the data, such as the composition of codes in the PROCEDURES table (e.g., number, number with letters, symbols like "\$" or "?") and provides insights into the original value definitions for study variables in the MEDICAL_OBSERVATIONS or SURVEY_OBSERVATIONS tables. Additionally, by assessing the content of the ConcePTION CDM tables the user can confirm that each table was fed appropriately.

293 Level 2

- Step 2.3 highlights records where dates fall outside the observation period (Figure 4). The construction of this period is a crucial step. Start dates of observation can be obtained from various sources, usually inhabitant registries. However, accessibility to these sources may vary and alternative resources such as first visit to a general practitioner are used. In figure 4, the high percentages of dates outside the observation period indicate that the current observation period fails to capture all relevant events.
- Moreover, Level 2 assesses the presence of subjects across the CDM tables. Ideally, all *person_id* in the CDM tables should be in the PERSONS table. An error in step 4 indicates a need to re-evaluate the design of the PERSONS table.
- 303 Level 3

14

304 In Level 3, DQAs become more extensive, as their goal is to facilitate the evaluation of fitness-305 for-purpose. Figure 5 illustrates a demographic tree indicating a similar distribution between 306 females and males. However, the study focus of ConcePTION is on females and young males. 307 It is possible that fathers have been included in the study population, which does not align with 308 the study requirements but is not necessarily an error. Another example is gestational diabetes 309 diagnostic codes in males. This could be explained by recording diagnoses under male 310 children. However, this percentage should be low to reflect the reality of the condition, 311 otherwise it may indicate an error.

- 312 In level 3, one of the checks is distribution analysis of start and end dates of follow-up, by year 313 and month. In Figure 6 all records start in January and July of 2004. This pattern indicates a potential ETL specification to filter out records outside the study period of interest. The peak 314 315 in July suggests imputation due to missing data in date of birth, which has been used as start 316 of observation.
- 317 Level 3 plays a crucial role in detecting and reflecting the consequences of technical errors 318 during L1, L1b, and L2 and highlights any errors from the data generation processes. By 319 identifying and addressing these issues, the goal is to improve the overall quality of the data 320 source. INSIGHT is an iterative process of running and updating, until the DAPs and PI have 321 confidence in the data source's quality.

15

Figure 3. Example of level 1 check

		2. Dates c	heck				
Table formatting		Check if date variables have the correct format and contain only allowable values for year, month and day. Report if any of the databases contain dates in the future.					
Dates check	Forderstime						
Missing data analysis	Explanations: a. If a date variable conta	ins errors in its format, those dates will be re	moved from further and	alysis (allowable val	ues check ar		
Output folder structure	counts of future dates).	as counts of errors for each table in the direc	top				
	c. If a date variable does d. If error_year is smaller	not contain any errors it will not be displayed than future_dates that means that for those I to the present year, but the day or month c	l in the table below. extra future dates the y	ear of the date vari	able that		
	Allowable values: a. year: 1995-present (in in error_year) b. month: 01-12 c. day: 01-31	some cases such as: dates that show follow	up, future dates are all	owed but they will s	till be count		
	The tables that will not un	dergo this analysis even if present in the dire	ectory due to absence	of date variables are	e:		
	a. PERSON_RELATIONS b. PRODUCTS	SHIPS					
	Based on errors in future a. blue: years before 1999 b. red: years before 1995 c. green: years in the futu d. black: no errors	only					
	Show 10 🗸 entries		S	earch:			
	table_name	table_directory	variable_name 🕴	error_format 🕴	error_yea		
	VISIT_OCCURRENCE	VISIT_OCCURRENCE_SPA201111.csv	visit_start_date	0			
	EVENTS	EVENTS_EXE.csv	start_date_record	0	49		
	EVENTS	EVENTS_PS.csv	start_date_record	0			
	EVENTS	EVENTS_PS.csv	end_date_record	0			
	EVENTS	EVENTS_SALM.csv	start_date_record	0	459		
	MEDICINES	MEDICINES_2005_SPF.csv	date_dispensing	0			
	PROCEDURES	PROCEDURES SD02003.csv	procedure date	0			
	PROCEDURES	PROCEDURES_SD02005.csv	procedure_date	0			
	PROCEDURES	PROCEDURES_SD02007.csv	procedure_date	0			
			· -				
	PROCEDURES	PROCEDURES_SDO2008.csv	procedure_date	0			
	Showing 1 to 10 of 39 en		Previous	1 2 3			
	3100010 10 10 01 33 61	nes	PIEVIDIN		4 Ne:		

16

Figure 4. Example of level 2 check

2.3 - Date values outside observation periods The table below shows shows the number of date values taking date taking place outside of the observation periods as specified in the OBSERVATION_PERIODS table, by table, date variable, and meaning: Show 50 ∨ entries Search: TABLE v.DATES Meaning Issues 🕴 Total Percenta EVENTS start_date_record (NOT ENTERED) 4578 42528 10. EVENTS start_date_record access_to_mental_health_service_comorbidity 580 6784 ŧ EVENTS start_date_record access_to_mental_health_service_primary 95365 826076 11. EVENTS start_date_record 856234 8991024 9 emergency_room_diagnosis EVENTS 856234 8991024 9. start date record emergency_room_presentation 1425621 EVENTS 144673 10 start_date_record exemption EVENTS start_date_record hospitalisation_primary 1585712 6862820 23 EVENTS start_date_record 1071344 5318087 20. hospitalisation secondary MEDICAL OBSERVATIONS mo_date measure_during_hospitalisation 6054 43816 13 MEDICINES date_dispensing dispensing_in_community_pharmacy 13766879 200060691 6 MEDICINES date dispensing dispensing_in_hospital_pharmacy_unspecified 2741080 38346942 7. MEDICINES date_prescription dispensing_in_community_pharmacy 0 0 MEDICINES 0 0 date_prescription dispensing_in_hospital_pharmacy_unspecified PROCEDURES 46972216 505311853 9. procedure date italian outpatient PROCEDURES procedure_date procedure_during_hospitalisation 2781140 14008393 19 SURVEY_ID 333694 1046685 31. survey_date birth_registry_mother 6753 37824 17. SURVEY ID survey_date death registry 98733 105625 SURVEY_ID survey_date induced_termination_registry 93 SURVEY_ID survey_date spontaneous_abortion_registry 37807 64708 58. 4088683 VACCINES 324401 7 vx admin date administration of vaccine unspecified VACCINES vx_record_date administration_of_vaccine_unspecified 324401 4088683 7 < >

Showing 1 to 21 of 21 entries

Previous 1 Next

Figure 5. Example of level 3 check

1. Population tree input source population at start study.

2. Compare Source versus Study population

3. Number of persons and follow up time by age at start follow up and year of start follow up

4. Persontime distribution by age, sex and calendar year (CountPersonTime)

5. Persontime by Year Month (CountPersonTime)

6. Duration for persons to be registered in the study population after birth (weeks)

7. Median follow-up for persons that are registered in the study population within 8 weeks after birth by year of birth

This report is focusing on the follow up time of the subjects. The following topics are evaluated: Age distribution of the source (initial database).

• The effect of the appliance of the exclusion steps (see the FlowChartSourcetoStudy.rds file in the tmp folder) on


- the number of subjects and follow up time. The exclusion steps can be changed in Step_00_SetParameters.R
- · Follow up time characteristics in the study population (new study table after appliance of the exclusion steps)

1. Population tree input source population at start study.

		Number of females	¢	Number of males	
0	19153		20678		
1-4	84358		88739		
5-9	120746		120128		
10-14	137190		135811		
15-19	164186		160783		
20-24	183627		180210		
25-29	182617		178095		
30-34	169083		161563		
35-39	149400		138017		
40-44	136093		125430		

Showing 1 to 10 of 11 entries

Previous 1 2 Next



18

Figure 6. Example of level 3 check

year and month

vear and month

and month

and month

month



19

322 DISCUSSION

323 The use of RWD in research and decision-making has gained significant attention from regulatory agencies such as FDA, PMDA, and EMA. They have emphasized the importance 324 of valid and trustworthy RWD for generation of RWE.^{1,2} In this article, we present INSIGHT, a 325 tool to assess fit-for-use (research independent) and fit-for-purpose (research specific) of 326 327 RWD.

328 Studies including multiple data sources are becoming more popular especially in 329 pharmacoepidemiologic studies.¹⁹ With the abundance of healthcare data available, DAPs can 330 leverage various data sources including routine healthcare data, surveillance systems, 331 inhabitant registries, and more. However, the utility of these granular data sources relies on 332 their quality. Data quality encompasses several features, including representativeness, 333 precision, and accessibility, among other dimensions. To evaluate quality, EMA and Heads of 334 Medicines Agency have proposed the DQF for EU medicines regulation which includes five 335 quality dimensions: reliability, extensiveness, coherence, timeliness, and relevance.²⁰ We 336 have mapped INSIGHT's data quality dimensions to Kahn's framework (left), and the EMA 337 DQF (right) (Supplemental File 2). INSIGHT is built on the ConcePTION CDM, which is utilized 338 by multiple networks (ConcePTION project, VAC4EU, EU & PV network, SIGMA consortium) 339 and in many regulatory required multi-data source studies commissioned or requested by EMA. 340

341 CDMs play a vital role in facilitating data quality assessment when using secondary-use data.²¹ 342 While DQAs aid assessing fitness-for-purpose, it is essential to recognize that data quality is 343 influenced by numerous factors, mostly the health care system, the purpose of data recording 344 and the type of data recorder. INSIGHT DQAs provide a generic and transparent overview of 345 data quality indicators, aiming to identify inconsistencies in the data, which can be categorized 346 into three main types: extraction or convention errors, script errors, and patterns for 347 acknowledgment and documentation. The outputs support the study team to understand the 348 data that is being utilized and the semantic harmonization. The purpose of DQAs varies across 349 these contexts, ranging from rectifying extraction errors to fine-tuning scripts to suit project 350 requirements. Additionally, documenting data patterns ensures accurate interpretation and 351 understanding of data nuances and limitations.

352 Previous data quality assessment tools

353 Various research networks have developed their own DQA processes with varying levels and 354 indicators. For example, the US FDA Sentinel uses a four-level approach focusing on 355 completeness and validity, accuracy and integrity, consistency of trends, and plausibility.^{9,22} 356 The EUROCAT network, has a comprehensive DQA process, that includes indicators such as

20

357 case ascertainment, accuracy of diagnoses, data completeness, timeliness, and availability of denominator data.^{23,24} Researchers using the OMOP CDM have access to tools like the White 358 359 Rabbit and the Data Quality Dashboard (DQD) for assessing data quality at source data and CDM-standardized database. 8,25-27 360

A comparison of DQAs across six research networks revealed variations in the number of 361 quality checks, ranging from 875 up to 3234.²⁸ The DQAs processes also varied, including 362 differences in centralization, distributed coordination of DQAs, programing languages, and 363 364 staff involvement. These differences can be attributed to specific network requirements, 365 analytical focus, as well as the maturity of their DQA models.

366 Strengths and limitations

367 Our open-source DQA methodology was built during the ConcePTION project and has been 368 made generic and is adopted by other networks using the ConcePTION CDM. Our approval 369 system is based on a flexible approval form and relies on study requirements, over 370 predetermined conditions. However, there are limitations to be acknowledged. First, script 371 running time depends on hardware, data size and complexity. Components like the central 372 processing unit, random access memory, and computer data storage help determine process 373 efficiency. Second, the pipeline requires iterative reruns after data issues are fixed until 374 desired quality is achieved or at least, explained. Steps must be executed sequentially to avoid 375 downstream issues. Last, fit-for-purpose evaluation is time and resource-intensive. While 376 summary reports and dashboards aid assessment, automated detection of trends and 377 verification against external benchmarks need to be facilitated further. Automating outlier and 378 pattern detection is an area for future development given the increase complexity and limited 379 skilled human resources. Overall, the DQA workflow is subject to continuous improvements.

380 Implications for researchers and future research

381 The INSIGHT R scripts are openly available through GitHub, along with a training course for the Vaccine Monitoring Collaboration for Europe (VAC4EU) and educational videos to 382 383 encourage other stakeholders to adopt this DQA pipeline and adhere to principles of open 384 science. This tool has been already successfully implemented in EMA tendered risk 385 minimization studies (EUPAS31095, EUPAS21001), COVID vaccines effectiveness study 386 (EUPAS40404, EUPAS42504), Post-Authorization Safety Studies (EUPAS43593, EUPAS44424, EUPAS41725, EUPAS45461), and CONSIGN (EUPAS39226, EUPAS39438, 387 EUPAS40317).²⁹ As previously stated, INSIGHT is compliant with the proposed DQF for EU 388 389 medicines regulation launched in October 2022.

390 Interoperability between CDMs and their specific DQAs processes remains a challenge, as 391 each CDM must be used in conjunction with its customized tools. This implies that applying

21

392 external DQAs tools to an already CDM-standardized data source would require an additional 393 ETL process tailored to that CDM. To address this, we propose to establish standards and 394 guidelines for achieving interoperability across different CDMs. This would facilitate the exchange of DQAs tools and methodologies between research networks and regulatory 395 396 bodies, streamlining the quality assessment process.

397 CONCLUSION

398 In this article, we introduced INSIGHT, a comprehensive pipeline for conducting DQAs of 399 ConcePTION CDM-standardized datasets. The tool aims to facilitate the evaluation of the 400 fitness-for-use and fitness-for-purpose of RWD. By implementing this tool, researchers can 401 assess the adequacy and reliability of the data, ensuring that the evidence generated is robust 402 and reliable for studies on medicines and vaccines. INSIGHT is a valuable tool for evaluating 403 the quality of data sources and enhancing the credibility of RWD in clinical and regulatory 404 decision-making.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.30.23297753; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES

- U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence Program. Published 2023. Accessed February 1, 2023. https://www.fda.gov/media/120060/download
- Heads of Medicines Agency. European Medicines Agency HMA-EMA Joint Big Data Taskforce Summary Report. Accessed February 1, 2023. https://www.ema.europa.eu/en/documents/minutes/hma/ema-joint-task-force-bigdata-summary-report_en.pdf
- Trifirò G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? *J Intern Med*. 2014;275(6):551-561. doi:10.1111/joim.12159
- 4. Togo K, Yonemoto N. Real world data and data science in medical research: present and future. *Japanese Journal of Statistics and Data Science*. 2022;5(2):769-781. doi:10.1007/s42081-022-00156-0
- Illamola SM, Bucci-Rechtweg C, Costantine MM, Tsilou E, Sherwin CM, Zajicek A. Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. *Br J Clin Pharmacol.* 2018;84(2):215-222. doi:10.1111/bcp.13438
- 6. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. *Cochrane Database of Systematic Reviews*. 2014;2020(6). doi:10.1002/14651858.CD010236.pub2
- Qualls LG, Phillips TA, Hammill BG, et al. Evaluating Foundational Data Quality in the National Patient-Centered Clinical Research Network (PCORnet[®]). *eGEMs (Generating Evidence & Methods to improve patient outcomes)*. 2018;6(1):3. doi:10.5334/egems.199
- 8. Blacketer C, Defalco FJ, Ryan PB, Rijnbeek PR. Increasing trust in real-world evidence through evaluation of observational data quality. *Journal of the American Medical Informatics Association*. 2021;28(10):2251-2257. doi:10.1093/jamia/ocab132
- 9. Ball R, Robb M, Anderson S, Dal Pan G. The FDA's sentinel initiative-A comprehensive approach to medical product surveillance. *Clin Pharmacol Ther*. 2016;99(3):265-268. doi:10.1002/cpt.320
- Thurin NH, Pajouheshnia R, Roberto G, et al. From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. *Clin Pharmacol Ther*. 2022;111(1):321-331. doi:10.1002/cpt.2476
- 11. Kahn MG, Callahan TJ, Barnard J, et al. A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data. *eGEMs (Generating Evidence & Methods to improve patient outcomes)*. 2016;4(1):18. doi:10.13063/2327-9214.1244
- Bian J, Lyu T, Loiacono A, et al. Assessing the practice of data quality evaluation in a national clinical data research network through a systematic scoping review in the era of real-world data. *Journal of the American Medical Informatics Association*. 2020;27(12):1999-2010. doi:10.1093/jamia/ocaa245
- 13. Sturkenboom M, Braeye T, van der Aa L, et al. ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations. *Vaccine*. 2020;38:B8-B21. doi:10.1016/j.vaccine.2020.01.100
- 14. anDREa Consortium. anDREa. Accessed February 1, 2023. www.andrea-cloud.eu

- 15. Hoxhaj V. UMC-Utrecht-RWE/INSIGHT-Level1: V1. Zenodo. 2023. doi: 10.5281/zenodo.10035167.
- 16. Cid Royo A. and Elbers R. UMC-Utrecht-RWE/INSIGHT-Level1b: V1. Zenodo. 2023. doi: 10.5281/zenodo.10048081.
- 17. Hoxhaj V, and van den Bor R. UMC-Utrecht-RWE/INSIGHT-Level2: V1. Zenodo. 2023 doi: 10.5281/zenodo.10035169.
- 18. Hoxhaj V, Elbers R, and Alsina E. UMC-Utrecht-RWE/INSIGHT-Level3: V1. Zenodo. 2023. doi: 10.5281/zenodo.10035171.
- Pacurariu A, Plueschke K, McGettigan P, et al. Electronic healthcare databases in 19. Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open. 2018;8(9):e023090. doi:10.1136/bmjopen-2018-023090
- 20. EMA and Heads of Medicines Agency. Data Quality Framework for EU medicines regulation. Accessed February 1, 2023. https://www.ema.europa.eu/en/news/highquality-data-empower-data-driven-medicines-regulation-european-union
- 21. Trifirò G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275(6):551-561. doi:10.1111/joim.12159
- Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the 22. Sentinel System — A National Resource for Evidence Development. New England Journal of Medicine. 2011;364(6):498-499. doi:10.1056/NEJMp1014427
- 23. European Comission. Data Quality Indicators in EUROCAT. Accessed February 1, 2023. https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/DQI-List-of-Data-Quality-Indicators-since-2012.pdf
- 24. Loane M, Dolk H, Kelly A, Teljeur C, Greenlees R, Densem J. Paper 4: EUROCAT statistical monitoring: Identification and investigation of ten year trends of congenital anomalies in Europe. Birth Defects Res A Clin Mol Teratol. 2011;91(S1):S31-S43. doi:10.1002/bdra.20778
- 25. OHDSI. Data Quality Dashboard (DQD). Accessed February 1, 2023. https://ohdsi.github.io/DataQualityDashboard/
- OHDSI. CDM OHDSI Common Data Model. Accessed February 1, 2023. 26. https://github.com/OHDSI/CommonDataModel/releases
- 27. OHDSI. WhiteRabbit. Accessed February 1, 2023. https://github.com/OHDSI/WhiteRabbit
- 28. Callahan TJ, Bauck AE, Bertoch D, et al. A Comparison Of Data Quality Assessment Checks In Six Data Sharing Networks. eGEMs (Generating Evidence & Methods to *improve patient outcomes*). 2017;5(1). doi:10.13063/2327-9214.1287
- 29. Maisonneuve E, de Bruin O, Hurley E, et al. CONSIG-International Meta-Analysis Protocol & Statistical Analysis Plan (1.1). Zenodo. doi:10.5281/zenodo.7112746

medRxiv preprint doi: https://doi.org/10.1101/2023.10.30.23297753; this version posted October 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

FUNDING

The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

AUTHORS CONTRIBUTION

VH, CD, and MCJM started with the initial design; VH, RE, EA, and RvdB programmed the R scripts; VH and CLAN wrote the initial draft of the manuscript. VH, CLAN, JRA, RE, EA and MCJM, provided critical feedback and edited the manuscript. All authors have seen and approved the manuscript. The research leading to these results was conducted as part of the ConcePTION consortium. This paper only reflects the personal views of the stated authors.

ACKNOWLEDGMENTS

We would like to thank Rutger van den Bor for supporting the programming of INSIGHT Level 2, Claudia Bartolini for testing the scripts, and Rosa Gini for her expertise and collaboration throughout this project.

SUPPLEMENTARY MATERIAL

S1. Approval formS2. Theoretical mapping of INSIGHT to other DQFs

CONFLICT OF INTEREST STATEMENT

All authors have completed the ICMJE uniform disclosure form at <u>www.icmje.org/coi_disclosure.pdf</u> and declare: all authors received financial support through the ConcePTION project for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

INSIGHT PIPELINE AVAILABILITY

The quality check pipeline for ConcePTION CDM v2.2 instances is available as an opensource R scripts in the following link <u>https://github.com/UMC-Utrecht-RWE</u>. Protocol and Statistical Analysis Plan (SAP) can also be found there. Furthermore, a training course for DAPs and researchers is available upon request.

STUDY REGISTRATION

This research was registered in EU PAS registration with number EU50142.